- Home
- ZEPP vs BRNS Comparison
ZEPP vs BRNS Comparison
Compare ZEPP & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZEPP | BRNS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.7M | 30.4M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZEPP | BRNS |
|---|---|---|
| Price | $4.81 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 38.1K | ★ 54.9K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $778.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.85 | $0.51 |
| 52 Week High | $61.50 | $1.83 |
Technical Indicators
Market Signals| Indicator | ZEPP | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 59.44 |
| Support Level | $4.04 | $0.65 |
| Resistance Level | $5.71 | $0.74 |
| Average True Range (ATR) | 0.41 | 0.05 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 39.89 | 67.06 |
Price Performance
Historical ComparisonAbout ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands. Geographically, the group generates revenue from Asia-Pacific, Europe, North America and others.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.